Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel

Jie Huang1,*, Bryan Howie2,*, Shane McCarthy1, Yasin Memari1, Klaudia Walter1, Josine L. Min3, Petr Danecek1, Giovanni Malerba4, Elisabetta Trabetti4, Hou-Feng Zheng5,6,7, UK10K Consortium†, Giovanni Gambaro8, J. Brent Richards5,6,7,9, Richard Durbin1, Nicholas J. Timpson3, Jonathan Marchini10,11,# & Nicole Soranzo1,12,#

Imputing genotypes from reference panels created by whole-genome sequencing (WGS) provides a cost-effective strategy for augmenting the single-nucleotide polymorphism (SNP) content of genome-wide arrays. The UK10K Cohorts project has generated a data set of 3,781 whole genomes sequenced at low depth (average 7x), aiming to exhaustively characterize genetic variation down to 0.1% minor allele frequency in the British population. Here we demonstrate the value of this resource for improving imputation accuracy at rare and low-frequency variants in both a UK and an Italian population. We show that large increases in imputation accuracy can be achieved by re-phasing WGS reference panels after initial genotype calling. We also present a method for combining WGS panels to improve variant coverage and downstream imputation accuracy, which we illustrate by integrating 7,562 WGS haplotypes from the UK10K project with 2,184 haplotypes from the 1000 Genomes Project. Finally, we introduce a novel approximation that maintains speed without sacrificing imputation accuracy for rare variants.
Statistical inference of missing genotypes (imputation), where genotyped markers from SNP arrays are used to impute unobserved genotypes from haplotype panels such as the HapMap data, has been instrumental to the discovery of thousands of complex trait loci in meta-analyses of genome-wide association studies (GWAS)\(^1,2\). Whole-genome sequencing (WGS) provides near-complete characterization of genetic variation, but it is still prohibitive for researchers to conduct WGS on the large number of samples that are needed to study phenotypic associations of low-frequency and rare genetic variants (minor allele frequency (MAF) < 1–5% and < 1% respectively). Recently, the 1000 Genomes Project (1000GP) has provided phased haplotypes for more than a thousand samples from diverse worldwide populations, thereby boosting variant coverage and imputation quality, particularly for variants with MAFs of 1–5% (ref. 3). Imputation using this large reference panel has been made computationally efficient by pre-phasing of GWAS samples\(^3\) and approximations that select a subset of reference haplotypes\(^5\).

Here we describe a novel WGS imputation panel comprising 3,781 samples from the UK10K Cohorts project\(^6\). We show that this reference panel greatly increases accuracy and coverage of low-frequency variants relative to a panel of 1,092 individuals from the 1000GP. In addition, we show that imputation accuracy can improve substantially when reference haplotypes are re-phased after initial WGS genotype calling. We present a practical solution for combining imputation reference panels to increase variant coverage, and we introduce a new approximation that maintains the speed of existing approximations while achieving higher accuracy.

**Results**

**The UK10K imputation panel.** The UK10K Cohorts Project\(^6\) includes two population samples from the UK (http://www.uk10k.org/studies/cohorts.html). The TwinsUK registry comprises unselected, mostly female volunteers ascertained from the general population through national media campaigns in the UK\(^7\). The Avon Longitudinal Study of Parents and Children (ALSPAC) is a population-based birth cohort study that includes two population samples from the UK (http://www3.bristol.ac.uk/alspac/). The UK10K Cohorts Project\(^6\) ---&gt; 13,000 pregnant women resident in Bristol (formerly Avon), UK\(^8\). A total of 1,990 individuals from TwinsUK and 2,040 individuals from ALSPAC were consented for sequencing. Variant sites and genotype likelihoods were called using SAMtools\(^9\), and genotypes were refined and phased using BEAGLE\(^8\). After QC, 45,492,035 variant sites (42,001,210 single-nucleotide variants and 3,490,825 insertion/deletions (INDELs)) were retained (Table 1) in 1,854 and 1,927 individuals in the TwinsUK and ALSPAC panels, respectively. We developed new software functionality for merging haplotype reference panels (Supplementary Note 1 and Supplementary Fig. 1). For imputation using the merged panel, we performed a leave-one-out cross-validation on a pseudo-GWAS of UK ancestry, corresponding to a sub-sample of 1,000 individuals from the UK10K WGS data set (500 from TwinsUK and 500 from ALSPAC). For this experiment, we removed each sample from the reference panel in turn, selected 13,413 sites on chromosome 20 from the Illumina 610 k bead chip (pseudo-GWAS panel), and imputed all other sites on this chromosome from a given reference panel. We conducted the imputation with three haplotype reference panels: the 1000GP Phase 1 panel, the ‘original’ UK10K panel produced by initial genotype refinement and haplotyping with BEAGLE, and a ‘re-phased’ UK10K panel that was generated by using SHAPEIT v2 (ref. 11) to estimate haplotypes from the BEAGLE genotypes (Supplementary Fig. 2). The accuracy of imputed variants was calculated as the squared Pearson correlation coefficient ($r^2$) between imputed genotype dosages in (0–2) and masked sequence genotypes in (0,1,2). The results were stratified into non-overlapping MAF bins for plotting.

The results of this experiment are shown in Fig. 1a, which focuses on variants with MAF < 5%. The corresponding plot for all MAF is shown in Supplementary Fig. 3. Both UK10K reference panels (blue dotted and solid lines) produced higher accuracy than the 1000GP panel (black line), with greater gains at lower frequencies. These trends were expected due to the larger sample size and better ancestry matching of the UK10K reference panel to the pseudo-GWAS data. Notably, the UK10K reference panel yielded much higher imputation accuracy after re-phasing with SHAPEIT v2 (solid versus dotted blue lines): the mean $r^2$ at low frequencies increased by > 0.1 (20%) after re-phasing, which implies a substantial boost in the power to detect associations. A large imputation panel is a resource that can inform a variety of association studies, so these results suggest that taking the time to improve a WGS panel’s haplotype quality could have substantial downstream benefits.

**Table 1 | Descriptives for the UK10K and 1000GP reference panels used for imputation.**

<table>
<thead>
<tr>
<th></th>
<th>UK10K</th>
<th>1000GP(Phase 1 v3)</th>
<th>Combined</th>
<th>Overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>N samples (% European)</td>
<td>3,781 (100%)</td>
<td>1,092 (34.7%)</td>
<td>4,873</td>
<td>—</td>
</tr>
<tr>
<td>N total sites in final release</td>
<td>45,492,035</td>
<td>39,527,072</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>N total sites after filtering*</td>
<td>26,032,603</td>
<td>32,449,428</td>
<td>42,359,694</td>
<td>16,122,337</td>
</tr>
<tr>
<td><strong>Autosome SNPs</strong></td>
<td>23,411,632</td>
<td>1,698,262</td>
<td>2,407,858</td>
<td>661,223</td>
</tr>
<tr>
<td><strong>Autosome INDELs</strong></td>
<td>1,698,262</td>
<td>1,370,819</td>
<td>2,407,858</td>
<td>661,223</td>
</tr>
<tr>
<td><strong>Chr X SNPs</strong></td>
<td>858,380</td>
<td>23,411,632</td>
<td>32,449,428</td>
<td>42,359,694</td>
</tr>
<tr>
<td><strong>Chr X INDELs</strong></td>
<td>858,380</td>
<td>1,223,328</td>
<td>1,612,230</td>
<td>469,478</td>
</tr>
</tbody>
</table>

*For UK10K, the following sites were excluded: 18,180,633 singletons that do not exist in 1000GP, 1,064,168 multi-allelic sites and 214,631 mis-matched alleles sites. For 1000GP, the following sites were excluded: 7,053,246 singletons that do not exist in UK10K, 23,932 sites with a SNP and an INDEL at the same position and 443 within large structural deletions. The bold indicates that these four categories of variants are subsets of the N total sites after filtering.
Evaluation of combining two reference panels. It is becoming increasingly common for investigators to conduct their own WGS of particular study populations, and a natural goal is to combine these data sets with publicly available reference panels (such as 1000GP) to increase sample size and variant coverage for imputation of GWAS cohorts. This is already a ubiquitous problem, and there are multiple ways to integrate WGS data sets that require different levels of data sharing and computing power. In this work, we suggest a simple approach that should be feasible for most groups that have sufficient computational resources for GWAS imputation. Our approach is to take two-phased reference panels and reciprocally impute them up to the union set of these data sets with publicly available reference panels (such as 1000GP) to increase sample size and variant coverage for imputation of GWAS cohorts. This is already a ubiquitous problem, and there are multiple ways to integrate WGS data sets that require different levels of data sharing and computing power. In this work, we suggest a simple approach that should be feasible for most groups that have sufficient computational resources for GWAS imputation. Our approach is to take two-phased reference panels and reciprocally impute them up to the union set of variants, then use this combined panel for GWAS imputation; we have implemented this functionality in IMPUTE2 (ref. 1) (details are shown in Supplementary Table 1 and Supplementary Note 1).

To evaluate this new functionality, we used a combined 1000GP + UK10K panel to perform imputation with pseudo-GWAS data sets drawn from the UK and Italy (details below). In each of these comparisons, we imputed all available reference variants and stratified them by expected $r^2$, which is a confidence metric produced by IMPUTE2 (also known as ‘info’ in the software output). Unlike the true $r^2$ metric, which is usually calculated by masking and imputing ‘truth’ genotypes, the expected $r^2$ metric allows direct comparisons of reference panel performance across study populations that have substantially different sets of genotyped truth variants. We have found that predicted $r^2$ values tend to be larger than true $r^2$ values for low-frequency variants (for example, only $\sim 2/3$ of variants with expected $r^2 \geq 0.4$ and MAF <5% have true $r^2 \geq 0.4$), so the absolute numbers of high-confidence imputed variants reported in this section should be treated as upper bounds; the emphasis is on qualitative patterns between reference panels and between study populations.

Figure 1b shows how a combined 1000GP + UK10K panel (red) produced by this method performed against each panel separately (1000GP, black; UK10K, blue) when imputing a pseudo-GWAS of UK ancestry. For these evaluations, we used UK10K and 1000GP haplotype panels rephased using SHAPEIT v2, which were previously shown to yield more accurate imputation compared with the corresponding ‘original’ haplotypes. The combined and UK10K panels produced very similar numbers of high-confidence imputed variants at MAFs of 0.5% and higher, implying that the combined panel is neither helpful nor harmful for imputing common and low-frequency variants when a large, population-specific panel is available. On chromosome 20, the combined panel added 2,356 high-confidence rare variants that were not captured by the UK10K panel (MAF <0.5%; 4% increase), which could reflect mutations that have drifted to very low frequencies in the UK but persist on the same haplotype background elsewhere in Europe.
Figure 1c provides the results of a similar evaluation carried out in a population in northern Italy (INCIPE cohort), also based on chromosome 20. The INCIPE cohort was newly genotyped in this study, using Illumina HumanCoreExome-12v1-1 arrays. After stringent QC (Online Supplementary Methods), chromosome 20 genotypes from 6,300 SNPs in 2,145 participants were used to drive imputation with each reference panel. In this data set the UK10K reference panel outperformed the 1000GP panel in all frequency bins, despite the fact that the 1000GP includes a panel (TSI, or 'Toscani in Italia') that is genetically more similar to the study population. This confirms previous findings\cite{13} that reference sample size is often more important than population matching. As before, the combined 1000GP + UK10K panel yielded a larger number of high-confidence imputed variants than matching. The full UK10K imputing the INCIPE pseudo-GWAS data with the UK10K but it does not sacrifice imputation accuracy at rare and low-frequency variants. Our investigation of these variants led us to develop a new approximation that uses local (rather than region-wide) haplotype sharing to choose a subset of reference haplotypes (see Supplementary Note 2 for details). This approximation delivers a speed boost similar to that of the existing $k_{hap}$ approximation, but it does not sacrifice imputation accuracy at rare and low-frequency variants. For example, Fig. 1d shows the results of imputing the INCIPE pseudo-GWAS data with the UK10K reference panel (see also Supplementary Fig. 5). The full UK10K panel produced the highest accuracy (solid blue line), whereas the $k_{hap}$ approximation based on Hamming distance (solid orange line) was less accurate for SNPs with MAF < 5%. By contrast, our new approximation based on haplotype tract sharing (dashed orange line) was nearly as accurate as the full reference panel, at ~10% of the computing time (see also Supplementary Fig. 6). All of these strategies for choosing reference haplotypes improved slightly (1–5% increase in mean $r^2$) when the 1000GP haplotypes were added to the UK10K panel, but their relative accuracies remained similar to those shown in Fig. 1d. Further speed improvements are possible for a modest price in accuracy (see Supplementary Note 2).

**Discussion**

As WGS becomes a standard tool for population and disease genetics, there will be many questions about how to design sequencing studies, how to process the data, how to combine data across studies, and how to limit the computational costs of downstream analysis. With data from one of the most ambitious population sequencing studies to date, we have demonstrated the value of a large, UK-specific reference panel for imputation in British cohorts and in other European populations. Our results show that state-of-the-art phasing methods like SHAPEIT v2 are essential for creating high-quality haplotype panels. Combining WGS data across studies is a desirable goal, and we have implemented an approach in IMPUTE2 that can integrate sets of phased haplotypes to produce a unified reference panel; other strategies for combining WGS data may improve haplotype quality, but our approach has the advantage of being relatively simple and fast. Finally, we have proposed a new approximation that will help reduce the trade-off between imputation speed and accuracy as reference panels continue to grow. The novel strategies we have presented will inform other investigators who wish to use WGS reference panels for imputation, and they will spur additional methods development as population sequencing resources proliferate.

Future efforts to combine multiple large low-coverage sequencing datasets into a substantially larger haplotype resource will likely increase imputation performance, especially at variants with frequencies below 0.1%. We generated a combined reference panel with 42.4 million imputable sites, which is much larger than the 26.6 million imputable sites in the UK10K panel or 32.5 million imputable sites in the 1000GP panel. The UK10K WGS haplotypes for 3,781 samples are available for download from the European Genome-phenome Archive (http://www.ebi.ac.uk/ega/) under managed access conditions (http://www.uk10k.org/ access). The functionality described in this work is available from the IMPUTE2 website (http://www.sph.umich.edu/sv/ impute/impute_v2.html) and the SHAPEIT v2 website (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html).

**Methods**

**Sample collections.** The ALSPAC is a long-term health research project. More than 14,000 mothers enrolled during pregnancy in 1991 and 1992, and the health and development of their children has been followed in great detail ever since\cite{14}. A random sample of 2,040 study participants was selected for WGS. The ALSPAC Genetics Advisory Committee approved the study and all participants gave signed consent to the study.

The Department of Twin Research and Genetic Epidemiology, is the UK’s only twin registry of 11,000 identical and non-identical twins between the ages of 16 and 85 years (ref. 14). The database used to study the genetic and environmental aetiology of age-related complex traits and diseases. The St Thomas’s Hospital Ethics Committee approved the study and all participants gave signed consent to the study.

**Sequence data production.** Low-read depth WGS was performed in the TwinsUK and ALSPAC as part of the UK10K project. Methods for the generation of these data are described in detail as follows\cite{4,6}.

Low coverage WGS was performed at both the Wellcome Trust Sanger Institute and the Beijing Genomics Institute (BGI). DNA (1–3 μg) was sheared to 100–1,000 bp using a Covaris E210 or E220 (Covaris, Woburn, MA, USA). Sheared DNA was size subjected to Illumina paired-end DNA library preparation. Following size selection (300–500 bp insert size), DNA libraries were sequenced using the Illumina HiSeq platform as paired-end 100 base reads according to manufacturer’s protocol.

Data generated at the Sanger Institute and BGI were aligned to the human reference separately by the respective centres. The BAM files produced from these alignments were submitted to the European Genome-phenome Archive. The Vertebrate Resequencing Group at the Sanger Institute then performed further processing.

Sequencing reads that failed QC were removed using the Illumina QA Pipeline, and the rest were aligned to the GRCh37 human reference, specifically the reference used in Phase 1 of the 1000GP (ftp://ftp1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/human_g1k_v37.fasta.gz). Reads were aligned using BWA (v0.5.9-r16) (ref. 4). This involved the following steps:

1. Index the reference fasta file:
   `bwa index -a bwtsw <reference_fasta>`
2. For each fastq file:
   `bwa aln -q 15 -f <sai_file> <reference_fasta> <fastq_file>`
3. Create SAM files [sam] using bwa sampe for paired-end reads:
   `bwa sampe -f <sam_file> <reference_fasta> <sai_file> <fastq_files>`
4. Create sorted BAM from SAM. For alignments created at the Sanger this was done using Picard (v1.36; http://picard.sourceforge.net/)
   `SamFormatConverter and samtools (v0.1.11) sort. For alignments created at the BGI, this was done using samtools (v0.1.8) view and samtools sort.
5. PCR duplicates reads in the Sanger alignments were marked as duplicate using the Picard MarkDuplicates, whereas in the BGI alignments they were removed using samtools rmdup.
6. Further processing to improve SNP and INDEL calling, including realignment around known INDELs, base quality score recalibration, addition of BAQ tags,
merging and duplicate marking followed that used for Illumina low coverage data in Phase I of the 1000GP. Software versions used for UK10K for the steps described were: GATK version 1.1.5-g6643284, Picard version 1.64 and samtools version 0.1.16.

SNP and INDEL calls were made using samtools/bcftools (version 0.1.8 or >-5791). bcftools/samtools/commit/70c74ofac09632175e8bf6ed01e0568048638b by pooling the alignments from 3,910 individual low coverage BAM files. All samples and all sites genotype likelihood files (bcf) were created with the samtools mpileup command: samtools mpileup -EDSVp -c0 -m3 -f0.2 ± 8000 -P ILLUMINA -g with the flags:

-C= Constant for downgrading mapping quality for reads containing excessive mismatches.

At a position, read maximally d reads per input BAM

Variants were then called using the following bcftools command to produce a VCF file:

cfctools view -m 0.9 -vcnG.

For calling on chromosome X and Y, the following settings were applied. The pseudo-autosomal region (PAR) was masked on chromosome Y in the reference fasta file. Male samples were called as diploid in the PAR on chromosome X and haploid otherwise. No calls were made on chromosome Y for female samples. Diploid/haploid calls were made using the -s option in bcftools view. The PAR regions were: X-PAR1 (60,001-2,699,520); X-PAR2 (154,931,044-155,260,560); Y-PAR1 (10,001-2,649,520); Y-PAR2 (59,034,050-59,363,566). The pipeline order to generate annotations to be used for recalibration. Recalibration for the UnifiedGenotyper was used to recall the sites/alleles discovered by samtools in existing in 1000GP. These sites were excluded to create a new set of VCF files, sites with inconsistent alleles with that of the 1000GP data, and singletons not polymorphic in UK10K. These sites were excluded to create a new set of VCF files, sites were then split into 3MB chunks with ±250 kb flanking regions. SHAPEIT v2 was used to re-quote the haplotypes. Phasing information from the SHAPEIT output was copied back to the original VCF files, with the phase removed for sites missing due to the 2% AF cutoff. The phased chunks were then recombined with vcf-phaselc join from the vcftools package.

The 1000GP Phase I integrated variant set release (v3) for low-coverage whole-genomes in NCBI build 37 (hg19) coordinates was downloaded from 1000GP FTP site (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521), 23 November 2011 (including pathogen sequences). This called and phased haplotypes for a total of 1,092 samples and 32,449,428 sites. The VCF-QUERY tool was used to convert the new VCF files into phased haplotypes and legend files for IMPUTE2. VCF files were converted to binary ped (bed) format and multi-allelic sites excluded, and files were then split into 3MB chunks with ±250 kb flanking regions. SHAPEIT v2 was used to re-quote the haplotypes. Phasing information from the SHAPEIT output was copied back to the original VCF files, with the phase removed for sites missing due to the 2% AF cutoff. The phased chunks were then recombined with vcf-phaselc join from the vcftools package.

For the INCIPE study, 6,200 Caucasian participants were randomly chosen from the lists of registered patients of 62 randomly selected general practitioners based in four geographical areas in the Veneto region, North-eastern Italy. A total of 2,258 samples were genotyped by Illumina HumanCoreExome-12v1-1 platform. A total of 342,585 variants were called using Illumina GEMCALL algorithm, 244,394 of which are exonic variants. We conducted further QC as follows to determine sample and SNP quality. At sample level, we applied the following criteria (i) sample identity was validated through genotyping with an independent typing platform (Sequenom). No samples failed this step. (ii) Twelve pairs of duplicate samples, defined as pairs of individuals with ≥98% concordance genome-wide, were identified. The sample with the lowest call rate of the pair was excluded. (iii) Supplied gender was compared with the inferred gender (heterozygosity on sample chrX, or the proportion of chrX SNPs called AB). A Gaussian mixture model was used to find adaptive thresholds Mmax and Fmin.
overall, the maximum male and minimum female heterozygosity on chrX. Overall, 55 samples had chrX heterozygosities that were between Mmax and Mmin, and were excluded from analysis. (v) Call rate: 90 samples with call rates below 95% were excluded from analysis. (vi) 88 samples with autosomal heterozygosity (that is, the proportion of all SNPs with an heterozygous call) score ≥ 3 standard deviations away from the mean were excluded. (vii) Finally, five samples were recommended for exclusion where the normalised magnitude of intensity signals in both channels falls below 0.9. Overall, of the total of 2,258 samples genotyped, 2,145 passed QC filters while 113 samples failed QC filters as indicated above, with some samples failing multiple QC filters. At SNP level, we excluded variants with missingness rate ≥ 3% or Hardy-Weinberg disequilibrium \( P < 1 \times 10^{-5} \). We also checked all alleles to confirm that they are on the positive strand of the human genome by comparing alleles against the 1000G and UK10K data. At the end, there were a total of 346,941 polymorphic variants on autosomes, and 8,822 of those on chromosome 20 were retained for analysis.

**Pseudo-GWAS panel:** for our imputation evaluation, we used 6,300 SNPs on chromosome 20 to mimic a SNP chip in a pseudo-GWAS data set. Before imputation, the two pseudo-GWAS data sets were pre-phased using SHAPEIT v2 (ref. 11) to increase phasing accuracy. The UK10K panel was phased jointly with the entire WGS data set. The INCICE pseudo-GWAS of 2,145 participants was pre-phased separately.

SHAPEIT v2 was used also for re-phasing the reference haplotypes provided 1000GP and UK10K projects. Per the recommendation of the software, the mean size of the windows in which conditioning haplotypes are defined is set to 0.5MB, instead of 2MB used for pre-phasing GWAS. Owing to the significantly higher number of variants in the WGS data, the re-phasing was conducted by 3MB chunk with 250 kb buffering regions, rather than by whole chromosomes as for the pseudo-GWAS. Imputation was carried out on the same chunks with the same flanking regions.

The following three steps were used to merge two WGS reference panels using IMPUTE2 (version 2.3 and later):

1. Impute the variants that are specific to panel 1 (1000GP) into panel 2 (UK10K).
2. Impute the variants that are specific to panel 2 (UK10K) into panel 1 (1000GP).
3. Treat the imputed haplotypes in both panels (with the union of variants from both) as known (that is, take the best-guess haplotypes) and impute the GWAS cohort in the usual way.

The commands for combining haplotypes with the 1000GP and UK10K data are given in Supplementary Note 3. Imputation of genotypes from the three phased reference panels (UK10K, 1000GP, and 1000GP + 1000GP) into the two test panels was carried out on chromosome 20 split in 3MB chunks with 250 kb buffer regions. Imputation was performed using standard parameters with IMPUTE2, for example:

```bash
/impute2 \
m-genetic_map_chr20_combined.b37.txt \n-h chr20.10k.hap.gz \n-i chr20.10k.legend.gz \n-known_haps.g chr20.incep2gwas.known_haps.gz \n-k_hap 10000 \n-int 3e6 6e6 \n-Nr 20000 \n-buffer 250 \n-use_prephased_g \n-o.gz \n-o chr20.10k.incep2gwas.uk10k.Ref.impute2
```

In Fig. 1a,d, the accuracy of imputed variants was calculated as the Pearson correlation coefficient \( r \) between imputed genotype dosages in \( 0–2 \) and masked sequence genotypes in \( 0.1,2 \). The results were stratified into non-overlapping MAF bins for plotting. In Fig. 1b,c, the numbers of variants in different imputation accuracy bins were estimated via the expected \( r^2 \) (‘info’ metric) produced by IMPUTE2 (ref. 13). As discussed in the main text, this metric is biased upward relative to the true \( r^2 \), so the numbers of high-confidence variants in these figures should be interpreted as upper bounds.

**References**


**Acknowledgements**

This study makes use of data generated by the UK10K Consortium. The Wellcome Trust provided funding for UK10K (award W091310). N.S. is supported by the Wellcome Trust (Grant Codes WT098051 and W091310), the European Commission (EUF7 EPIGENESIS Grant Code 257082 and BLUEPRINT Grant Code HEALTH-F5-2011-282510) and the NIH. J.B.R. is funded by the CHB, QCDM, FRQS and the Jewish General Hospital. H.-F.Z. is supported by Canadian Institutes of Health Research. J.M. acknowledges support from the ERC (Grant no. 617306). NIT works in a unit supported by the UK Medical Research Council (MRC) (MC_UU_12103/3). For ALSPAC, we are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. For further details concerning the generation of UK10K sequence data, please see extended methods in reference 6. Key contributing studies from the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium appear in the lipids meta-analysis group, but we also acknowledge the support and contribution of the resource more generally. A full description of the collection and its component studies can be found here: DOI: 10.1371/journal.pone.0071345.

**Author contributions**

N.S. and J.M. designed the study. N.S., N.J.T., J.M., J.H. and B.H. wrote the manuscript. B.H. and J.M. performed the software and B.H. performed the analyses. Y.M., H.W., J.L.M., P.D., H.-F.Z., S.M., J.R.R., R.D., N.T., E.T., G.M. and G.G. contributed materials. All authors reviewed and approved the manuscript.

**Additional information**

**Accession Codes:** UK10K reference haplotypes are available from the European Genome-phenome archive under the accession codes EGAS00001000713 (EGA study) and EGAD00001000776 (EGA dataset) under managed access conditions (http://www.uk10k.org/data_access).

**Supplementary Information** accompanies this paper at http://www.nature.com/naturecommunications

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission information** is available online at http://npg.nature.com/reprintsandpermissions/

**How to cite this article:** Huang, J. et al. Improved imputation of low frequency and rare variants using the UK10K haplotype reference panel. *Nat. Commun.* 6:8111 doi:10.1038/ncomms9111 (2015).

---

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
University Avenue, PO Box 9700, Halifax, Nova Scotia, Canada B3K 6R8. Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia. Princess Al Jawhara Albrahim Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia. Macau University of Science and Technology, Avenida Wai long, Taipa, Macau 999078, China. Department of Medicine and State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, 21 Sassoon Road, Hong Kong. Population Health Research Institute, St George’s University of London, London SW17 0RE, UK. The Centre for Translational Omics - GO5gene, UCL Institute of Child Health, London WC1N 1EH, UK. School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia. Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. Renal Unit, Department of Medicine, University of Verona, 37126, Verona, Italy.